Cholesterol and apolipoprotein E in Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 20, Issue 2, 2005, Pages 91-96

  Reiss, Allison B ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Apolipoprotein E; Cholesterol

Indexed keywords

24 HYDROXYCHOLESTEROL; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ARGININE; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL DERIVATIVE; CYSTEINE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXYSTEROL; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CHOLESTEROL BLOOD LEVEL; EUROPE; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; NEUROFIBRILLARY TANGLE; NONHUMAN; NORTH AMERICA; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

EID: 17444406613     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/153331750502000208     Document Type: Article

References (63)

1. Clark C, Karlawish J: Alzheimer disease: Current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med. 2003; 138: 400-410.
2. Knopman D: Pharmacotherapy for Alzheimer's disease: 2002. Clinical Neuropharmacol. 2003; 26: 93-101.
3. Hardy J, Selkoe D: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002; 297: 353-356.
4. De Strooper B, Annaert W: Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000; 113:1857-1870.
5. Hartmann T: Cholesterol, A beta and Alzheimer's disease. Trend Neurosci. 2001; 24: S45-S48.
6. Launer L, White L, Petrovitch H, et al.: Cholesterol and neuropathologic markers of AD: A population-based autopsy study. Neurology. 2001; 57: 1447-1452.
7. Strittmatter W, Roses A: Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 4725-4727.
8. Puglielli L, Tanzi R, Kovacs D: Alzheimer's disease: The cholesterol connection. Nat Neurosci. 2003; 6: 345-351.
9. Dietschy JM, Turley SD: Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001; 12: 105-112.
10. Björkhem I, Lütjohann D, Diczfalusy U, et al.: Cholesterol homeostasis in human brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res. 1998; 39: 1594-1600.
11. Ballabh P, Braun A, Nedergaard M: The blood-brain barrier. An overview: Structure, regulation, and clinical implications. Neurobiol Dis. 2004; 16: 1-13.
12. Bjorkhem I, Meaney S: Brain cholesterol: Long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004; 24: 806-815.
13. Notkola I-L, Sulkava R, Pekkanen J, et al.: Serum total cholesterol, apolipoprotein E 4, and Alzheimer's disease. Neuroepidemiology. 1998; 17: 14-20.
14. Kivipelto M, Helkala E-L, Hänninen T, et al.: Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study. Neurology. 2001; 56: 1683-1689.
15. Wolozin B, Kellman W, Ruosseau P, et al.: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000; 57: 1439-1443.
16. Jick H, Zornberg G, Jick S, et al.: Statins and the risk of dementia. Lancet. 2000; 356: 1627-1631.
17. Fassbender K, Simons M, Bergmann C, et al.: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA. 2001; 98: 5856-5861.
18. Sparks D, Scheff S, Hunsaker J, et al.: Induction of Alzheimer-like b-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exper Neurol. 1994; 126: 88-94.
19. Simons M, Keller P, De Strooper B, et al: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 1998; 95: 6460-6464.
20. Buxbaum J, Geoghagen N, Friedhoff L: Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alz Dis. 2001; 3: 221-229.
21. Refolo L, Malester B, LaFrancois J, et al.: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7: 321-331.
22. Bodovitz S, Klein W: Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996; 271: 4436-4440.
23. Fonarow G, Watson K: Effective strategies for long-term statin use. Am J Cardiol. 2003; 92(1A): 27i-34i.
24. Sjogren M, Gustafsson K, Syversen S, et al.: Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cog Dis. 2003; 16(1): 25-30.
25. Fassbender K, Stroik M, Bertsch T, et al.: Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002; 59: 1257-1258.
26. Vaughan C, Gotto A, Basson C: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000; 35: 1-10.
27. Stoll L, McCormick M, Denning G, et al.: Antioxidant effect of statins. Drugs Today. 2004; 40: 975-990.
28. Petanceska S, DeRosa S, Sharma A, et al.: Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Molec Neurosci. 2003; 20: 395-406.
29. Vega G, Weiner M, Lipton A, et al.: Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003; 60: 510-515.
30. Brown J, Theisler C, Silberman S, et al.: Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004; 279: 34674-34681.
31. Kirsch C, Eckert G, Koudinov A, et al.: Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry. 2003; 36 Suppl 2: S113-S119.
32. Lutjohann D, Stroick M, Bertsch T, et al.: High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids. 2004; 69: 431-438.
33. Lund E, Guileyardo J, Russell D: cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA. 1999; 96: 7238-7243.
34. Bjorkhem I, Meaney S, Diczfalusy U: Oxysterols in human circulation: Which role do they have? Curr Opin Lipidol. 2002; 13: 247-253.
35. Lutjohann D, Papassotiropoulos A, Bjorkhem I, et al.: Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000; 41: 195-198.
36. Papassotiropoulos A, Lutjohann D, Bagli M, et al.: Plasma 24S-hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport. 2000; 11:1959-1962.
37. Lutjohann D, von Bergmann K: 24S-hydroxycholesterol: A marker of brain cholesterol metabolism. Pharmacopsychiatry. 2003; 36 Suppl 2: S102-S106.
38. Wolozin B, Brown J, Theisler C, et al.: The cellular biochemistry of cholesterol and statins: Insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Review. 2004; 10: 127-146.
39. Papassotiropoulos A, Streffer J, Tsolaki M, et al.: Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol. 2003; 60: 29-35.
40. Desai P, DeKosky S, Kamboh M: Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci Lett. 2002; 328: 9-12.
41. Kolsch H, Lutjohann D, Ludwig M, et al.: Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry. 2002; 7: 899-902.
42. Mahley R, Innerarity T, Rall S, et al.: Plasma lipoproteins: Apolipoprotein structure and function. J Lipid Res. 1984; 25:1277-1294.
43. Weisgraber K, Rall S, Mahley R: Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981; 256: 9077-9083.
44. Breslow JL: Genetic basis of lipoprotein disorders. J Clin Invest. 1989; 84: 373-380.
45. Herz J, Bock H: Lipoprotein receptors in the nervous system. Ann Rev Biochem. 2002; 71: 405-434.
46. Corder E, Saunders A, Strittmatter W, et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261: 921-923.
47. Roses A: Apolipoprotein E alleles as risk factors in Alzheimer's disease. Ann Rev Med. 1996; 47: 487-500.
48. Farrer L, Cupples L, Haines J, et al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278: 1349-1356.
49. Schmechel DE, Saunders AM, Strittmatter WJ, et al.: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein-E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993; 90: 9649-9653.
50. Breitner J, Wyse B, Anthony J, et al.: APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology. 1999; 53: 321-331.
51. Seshadri S, Drachman D, Lippa C: Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol. 1995; 52: 1074-1079.
52. Slooter A, Cruts M, Kalmijn S, et al.: Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch Neurol. 1998; 55: 964-968.
53. DeMattos R: Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J Molec Neurosci. 2004; 23: 255-262.
54. Ma J, Yee A, Brewer B, et al.: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994; 372: 92-94.
55. Castano E, Prelli F, Wisniewski T, et al.: Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein. Eur Bio chem J. 1995; 306: 599-604.
56. Bales K, Verina T, Cummins D, et al: Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 1999; 96: 15233-15238.
57. DeMattos R, Cirrito J, Parsadanian M, et al.: ApoE and clusterin cooperatively suppress Abeta levels and deposition. Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004; 41:193-202.
58. Bazin H, Marques M, Owens A, et al.: Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. Biochemistry. 2002; 41: 8203-8211.
59. Judson R, Brain C, Dain B, et al.: New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis. 2004; 177:345-351.
60. Marz W, Scharnagl H, Hoffmann M, et al.: The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J. 2004; 25: 2109-2119.
61. Yasojima K, Schwab C, McGeer EG et al.: Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000; 887: 80-89.
62. Mahley R, Rall S: Apolipoprotein E: far more than a lipid transport protein. Ann Rev Genom Hum Genet. 2000; 1: 507-537.
63. Davignon J, Gregg R, Sing C: Apolipoprotein E polymorphism and arteriosclerosis. Arteriosclerosis. 1988; 8: 1-21.